Literature DB >> 22969882

Magnetic fluid hyperthermia induced by radiofrequency capacitive field for the treatment of transplanted subcutaneous tumors in rats.

Xu-Hong Li1, Peng-Fei Rong, He-Kun Jin, Wei Wang, Jin-Tian Tang.   

Abstract

Magnetic fluid hyperthermia (MFH) induced by a magnetic field has become a new heating technology for the treatment of malignant tumors due to its ability to heat the tumor tissue precisely and properly, and due to its significant therapeutic effects. In this study, MFH induced by radiofrequency capacitive field (RCF) for the treatment of transplanted subcutaneous tumors in rats, was investigated. A total of 50 rats bearing subcutaneous tumors were randomly divided into five groups, including i) a pseudo-treatment (PT) control group, ii) magnetic fluid (MF) group, iii) pure hyperthermia (PH) group, iv) magnetic fluid hyperthermia 1 (MFH1) group, and v) magnetic fluid hyperthermia 2 (MFH2) group. Tumors were irradiated for 30 min in the MFH1 group 24 h following injection of MF. Tumors were irradiated for 30 min in the MFH2 group 24 h following injection of MF, and irradiation was repeated for 30 min 72 h following injection of MF. Tumor volumes, tumor volume inhibition ratios and survival times in the rat model were examined. Temperatures of tumor cores and rims both rapidly reached the desired temperature (∼50°C) for tumor treatment within 5 to 10 min in the MFH1 and MFH2 groups, and we maintained this temperature level by manually adjusting the output power (70-130 W). Tumor volumes of the MFH1 and MFH2 groups were reduced compared to those of the PT, MF and PH groups. The inhibitory effect on tumor growth in the MFH2 group (91.57%) was higher compared to that in the MFH1 group (85.21%) and the other groups. The survival time of the MFH2 group (51.62±2.28 days) and MFH1 group (43.10±1.57 days) was increased compared to that of the PH, MF and PT groups. The results obtained show that MFH induced by RCF may serve as a potential and promising method for the treatment of tumors.

Entities:  

Year:  2011        PMID: 22969882      PMCID: PMC3438723          DOI: 10.3892/etm.2011.397

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  17 in total

Review 1.  [Standards and perspectives in locoregional hyperthermia].

Authors:  Bert Hildebrandt; Beate Rau; Johanna Gellermann; Thoralf Kerner; Annett Nicolaou; Jens-Uwe Blohmer; Ralf Ulrich Trappe; Hanno Riess; Peter Wust
Journal:  Wien Med Wochenschr       Date:  2004-04

Review 2.  Ablation of liver metastases: current status.

Authors:  Vincent L Flanders; Debra A Gervais
Journal:  J Vasc Interv Radiol       Date:  2010-08       Impact factor: 3.464

Review 3.  Evolving technology for thermal therapy of cancer.

Authors:  Paul R Stauffer
Journal:  Int J Hyperthermia       Date:  2005-12       Impact factor: 3.914

Review 4.  Thermal therapy, part 1: an introduction to thermal therapy.

Authors:  Riadh W Y Habash; Rajeev Bansal; Daniel Krewski; Hafid T Alhafid
Journal:  Crit Rev Biomed Eng       Date:  2006

5.  Inhibition of tumor growth by quercetin with increase of survival and prevention of cachexia in Walker 256 tumor-bearing rats.

Authors:  Camila A Camargo; Maria Eleonora F da Silva; Rodrigo A da Silva; Giselle Z Justo; Maria Cristina C Gomes-Marcondes; Hiroshi Aoyama
Journal:  Biochem Biophys Res Commun       Date:  2011-03-06       Impact factor: 3.575

6.  Radiofrequency field-induced thermal cytotoxicity in cancer cells treated with fluorescent nanoparticles.

Authors:  Evan S Glazer; Steven A Curley
Journal:  Cancer       Date:  2010-07-01       Impact factor: 6.860

7.  Nanoparticle preconditioning for enhanced thermal therapies in cancer.

Authors:  Mithun M Shenoi; Neha B Shah; Robert J Griffin; Gregory M Vercellotti; John C Bischof
Journal:  Nanomedicine (Lond)       Date:  2011-04       Impact factor: 5.307

Review 8.  Targeted hyperthermia using metal nanoparticles.

Authors:  Paul Cherukuri; Evan S Glazer; Steven A Curley
Journal:  Adv Drug Deliv Rev       Date:  2009-11-10       Impact factor: 15.470

9.  Characterization of aqueous dispersions of Fe(3)O(4) nanoparticles and their biomedical applications.

Authors:  Fong-Yu Cheng; Chia-Hao Su; Yu-Sheng Yang; Chen-Sheng Yeh; Chiau-Yuang Tsai; Chao-Liang Wu; Ming-Ting Wu; Dar-Bin Shieh
Journal:  Biomaterials       Date:  2005-03       Impact factor: 12.479

Review 10.  Applications of magnetic nanoparticles in medicine: magnetic fluid hyperthermia.

Authors:  Magda Latorre; Carlos Rinaldi
Journal:  P R Health Sci J       Date:  2009-09       Impact factor: 0.705

View more
  5 in total

1.  Effect of interleukin-2 treatment combined with magnetic fluid hyperthermia on Lewis lung cancer-bearing mice.

Authors:  Runlei Hu; Shenglin Ma; Xianfu Ke; Hong Jiang; Dongshan Wei; Wei Wang
Journal:  Biomed Rep       Date:  2015-11-05

2.  Preparation of Folic Acid-Targeted Temperature-Sensitive Magnetoliposomes and their Antitumor Effects In Vitro and In Vivo.

Authors:  Xihui Wang; Rui Yang; Chunyan Yuan; Yanli An; Qiusha Tang; Daozhen Chen
Journal:  Target Oncol       Date:  2018-08       Impact factor: 4.493

3.  Targeted hyperthermia after selective embolization with ferromagnetic nanoparticles in a VX2 rabbit liver tumor model.

Authors:  Hongliang Sun; Linfeng Xu; Tianyuan Fan; Hongzhi Zhan; Xiaodong Wang; Yanfei Zhou; Ren-jie Yang
Journal:  Int J Nanomedicine       Date:  2013-10-02

4.  Preparation of folic acid-conjugated, doxorubicin-loaded, magnetic bovine serum albumin nanospheres and their antitumor effects in vitro and in vivo.

Authors:  Rui Yang; YanLi An; FengQin Miao; MengFei Li; PeiDang Liu; QiuSha Tang
Journal:  Int J Nanomedicine       Date:  2014-09-04

5.  Effective elimination of liver cancer stem-like cells by CD90 antibody targeted thermosensitive magnetoliposomes.

Authors:  Rui Yang; Li Y An; Qin F Miao; Feng M Li; Yong Han; Hui X Wang; Dang P Liu; Rong Chen; Sha Q Tang
Journal:  Oncotarget       Date:  2016-06-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.